Tags: Drug.
Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1 kappa directed to CD2. The agent has shown potent immunomodulatory effects selectively suppressing the function of T and NK cells and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.